|
1
|
Polygenes, risk prediction, and targeted prevention of breast cancer.
|
N Engl J Med
|
2008
|
9.64
|
|
2
|
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
|
Nat Genet
|
2013
|
5.58
|
|
3
|
Gene-panel sequencing and the prediction of breast-cancer risk.
|
N Engl J Med
|
2015
|
4.77
|
|
4
|
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
|
Nat Genet
|
2013
|
4.35
|
|
5
|
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
|
JAMA
|
2012
|
3.85
|
|
6
|
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
|
J Natl Cancer Inst
|
2013
|
2.93
|
|
7
|
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
|
J Clin Oncol
|
2006
|
2.81
|
|
8
|
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
|
J Clin Oncol
|
2013
|
2.71
|
|
9
|
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
|
Nature
|
2012
|
2.66
|
|
10
|
Genetic susceptibility to breast cancer.
|
Mol Oncol
|
2010
|
2.52
|
|
11
|
An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).
|
Breast Cancer Res
|
2007
|
2.46
|
|
12
|
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
|
PLoS Genet
|
2013
|
2.39
|
|
13
|
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).
|
J Natl Cancer Inst
|
2006
|
2.25
|
|
14
|
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
|
Clin Cancer Res
|
2011
|
2.09
|
|
15
|
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
1.99
|
|
16
|
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk.
|
PLoS Genet
|
2013
|
1.88
|
|
17
|
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
|
J Clin Oncol
|
2007
|
1.83
|
|
18
|
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Cancer Res
|
2006
|
1.77
|
|
19
|
Germline RAD51C mutations confer susceptibility to ovarian cancer.
|
Nat Genet
|
2012
|
1.76
|
|
20
|
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.75
|
|
21
|
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.
|
Genet Epidemiol
|
2011
|
1.58
|
|
22
|
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.
|
PLoS Genet
|
2010
|
1.56
|
|
23
|
Breast-cancer risk in families with mutations in PALB2.
|
N Engl J Med
|
2014
|
1.50
|
|
24
|
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
|
Clin Cancer Res
|
2008
|
1.43
|
|
25
|
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
|
J Natl Cancer Inst
|
2010
|
1.41
|
|
26
|
Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations.
|
Genet Epidemiol
|
2012
|
1.39
|
|
27
|
More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
|
N Engl J Med
|
2017
|
1.39
|
|
28
|
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
|
Nat Commun
|
2013
|
1.36
|
|
29
|
Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.36
|
|
30
|
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
|
J Clin Oncol
|
2013
|
1.29
|
|
31
|
Incorporating tumour pathology information into breast cancer risk prediction algorithms.
|
Breast Cancer Res
|
2010
|
1.28
|
|
32
|
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
|
Breast Cancer Res
|
2011
|
1.22
|
|
33
|
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
1.17
|
|
34
|
Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Hum Mol Genet
|
2010
|
1.15
|
|
35
|
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC).
|
PLoS One
|
2012
|
1.13
|
|
36
|
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
|
PLoS Biol
|
2011
|
1.12
|
|
37
|
Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
|
Genes Chromosomes Cancer
|
2005
|
1.07
|
|
38
|
Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
|
J Med Genet
|
2013
|
1.05
|
|
39
|
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes.
|
Cancer Res
|
2011
|
1.05
|
|
40
|
Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies.
|
Genet Epidemiol
|
2010
|
1.04
|
|
41
|
High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia.
|
Int J Cancer
|
2011
|
1.04
|
|
42
|
The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Breast Cancer Res
|
2004
|
1.04
|
|
43
|
Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.
|
J Med Genet
|
2013
|
1.01
|
|
44
|
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.01
|
|
45
|
Familial relative risks for breast cancer by pathological subtype: a population-based cohort study.
|
Breast Cancer Res
|
2010
|
1.00
|
|
46
|
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
|
Breast Cancer Res
|
2014
|
0.99
|
|
47
|
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
|
Hum Mutat
|
2012
|
0.98
|
|
48
|
The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
0.96
|
|
49
|
Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants.
|
J Med Genet
|
2013
|
0.95
|
|
50
|
BRCA1 and BRCA2 cancer risks.
|
J Clin Oncol
|
2006
|
0.95
|
|
51
|
The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Hum Mutat
|
2011
|
0.92
|
|
52
|
No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.
|
Breast Cancer Res Treat
|
2008
|
0.90
|
|
53
|
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
|
J Natl Cancer Inst
|
2015
|
0.90
|
|
54
|
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
|
Breast Cancer Res
|
2014
|
0.89
|
|
55
|
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
|
Hum Mol Genet
|
2011
|
0.89
|
|
56
|
Two ATM variants and breast cancer risk.
|
Hum Mutat
|
2005
|
0.89
|
|
57
|
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.89
|
|
58
|
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.
|
Breast Cancer Res
|
2012
|
0.88
|
|
59
|
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
|
Hum Genet
|
2011
|
0.87
|
|
60
|
No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
|
Breast Cancer Res Treat
|
2008
|
0.84
|
|
61
|
Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.83
|
|
62
|
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.
|
Breast Cancer Res
|
2010
|
0.82
|
|
63
|
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Breast Cancer Res Treat
|
2008
|
0.82
|
|
64
|
Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.
|
PLoS One
|
2012
|
0.80
|
|
65
|
Clinical software development for the Web: lessons learned from the BOADICEA project.
|
BMC Med Inform Decis Mak
|
2012
|
0.80
|
|
66
|
Exploring the link between MORF4L1 and risk of breast cancer.
|
Breast Cancer Res
|
2011
|
0.79
|
|
67
|
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Breast Cancer Res Treat
|
2012
|
0.78
|
|
68
|
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Breast Cancer Res Treat
|
2009
|
0.78
|
|
69
|
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
|
Breast Cancer Res Treat
|
2012
|
0.75
|
|
70
|
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
|
J Natl Cancer Inst
|
2017
|
0.75
|
|
71
|
Corrigendum: Rare coding variants and X-linked loci associated with age at menarche.
|
Nat Commun
|
2015
|
0.75
|
|
72
|
Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast Cancer.
|
Am J Epidemiol
|
2017
|
0.75
|